Stand Up To Cancer
Stand Up To Cancer
Explore linked clinical trials.20 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 1 | 2026-10-06 | NCT05013216 | |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Active, not recruiting | Phase 3 | 2026-09-09 | NCT03803553 | |
| Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors | Solid Tumor | Active, not recruiting | Phase 1 | 2026-09-08 | NCT03875287 | |
| Lurbinectedin in FET-Fused Tumors | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, childhood malignant neoplasm, connective tissue neoplasm, desmoplastic small round cell tumor, neoplasm, osteosarcoma, sarcoma, undifferentiated (embryonal) sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-09-02 | NCT05918640 | |
| Health Education Approach to Lung Screening | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not applicable | 2026-08-25 | NCT06070870 | |
| Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies | Cancer of Gastrointestinal Tract, Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, Thoracic Neoplasms, digestive system disorder, digestive system neoplasm, head and neck cancer, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2026-08-06 | NCT05995821 | |
| Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-08-05 | NCT03220477 | |
| GENetic Education Risk Assessment and TEsting Study | Candidates for Hereditary Pancreatic Cancer Testing | Active, not recruiting | Not applicable | 2026-07-01 | NCT03762590 | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphomatoid papulosis, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-06-12 | NCT03602157 | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-05-11 | NCT04262154 | |
| ZN-c3 + Gemcitabine in Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm | Active, not recruiting | Phase 2 | 2026-05-04 | NCT06015659 | |
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Residual Cancer, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-05-04 | NCT04434040 | |
| Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials | cancer, neoplasm | Active, not recruiting | Not applicable | 2026-04-27 | NCT05886764 | |
| CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT03568422 | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, central nervous system cancer, childhood malignant neoplasm, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, nervous system disorder, refractory malignant neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-28 | NCT06208657 | |
| HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | Ewing sarcoma, Myosarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, myomatous neoplasm, neoplasm, osteosarcoma, rhabdomyosarcoma, sarcoma, synovial sarcoma, undifferentiated (embryonal) sarcoma | Recruiting | Phase 1 | 2026-01-22 | NCT04995003 | |
| Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 2 | 2025-10-01 | NCT03563248 | |
| A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity | Soft Tissue Sarcoma of the Extremity | Active, not recruiting | Phase 2 | 2023-11-18 | NCT03092323 | |
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, hormone-resistant prostate carcinoma, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2023-05-01 | NCT02881242 | |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, ureter cancer, ureteral disorder, urethra neoplasm, urethral disorder, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Active, not recruiting | Phase 2 | 2021-11-04 | NCT03179943 |